bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 2 from Evaluation of Algorithms Using Automated Health Plan Data to Identify Breast Cancer Recurrences
Authors: Aiello Bowles Erin J. , Kroenke Candyce H. , Chubak Jessica , Bhimani Jenna , O'Connell Kelli , Brandzel Susan , Valice Emily , Doud Rachael , Theis Mary Kay , Roh Janise M. , Heon Narre , Persaud Sonia , Griggs Jennifer J. , Bandera Elisa V. , Kushi Lawrence H. , Kantor Elizabeth D.
Published: March 2024

Supplementary Table 2 showing performance results from triangulation overall and among subpopulations
Supplementary Table S4 from Lung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies
Authors: Li Yafang , Xiao Xiangjun , Li Jianrong , Han Younghun , Cheng Chao , Fernandes Gail F. , Slewitzke Shannon E. , Rosenberg Susan M. , Zhu Meng , Byun Jinyoung , Bossé Yohan , McKay James D. , Albanes Demetrios , Lam Stephen , Tardon Adonina , Chen Chu , Bojesen Stig E. , Landi Maria T. , Johansson Mattias , Risch Angela , Bickeböller Heike , Wichmann H-Erich , Christiani David C. , Rennert Gad , Arnold Susanne M. , Goodman Gary E. , Field John K. , Davies Michael P.A. , Shete Sanjay , Marchand Loïc Le , Liu Geoffrey , Hung Rayjean J. , Andrew Angeline S. , Kiemeney Lambertus A. , Sun Ryan , Zienolddiny Shanbeh , Grankvist Kjell , Johansson Mikael , Caporaso Neil E. , Cox Angela , Hong Yun-Chul , Lazarus Philip , Schabath Matthew B. , Aldrich Melinda C. , Schwartz Ann G. , Gorlov Ivan , Purrington Kristen S. , Yang Ping , Liu Yanhong , Bailey-Wilson Joan E. , Pinney Susan M. , Mandal Diptasri , Willey James C. , Gaba Colette , Brennan Paul , Xia Jun , Shen Hongbing , Amos Christopher I.
Published: March 2024

Supplementary Table S4 shows the imputation quality score of identified variants in different studies.
Supplementary Table S1 from Lung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies
Authors: Li Yafang , Xiao Xiangjun , Li Jianrong , Han Younghun , Cheng Chao , Fernandes Gail F. , Slewitzke Shannon E. , Rosenberg Susan M. , Zhu Meng , Byun Jinyoung , Bossé Yohan , McKay James D. , Albanes Demetrios , Lam Stephen , Tardon Adonina , Chen Chu , Bojesen Stig E. , Landi Maria T. , Johansson Mattias , Risch Angela , Bickeböller Heike , Wichmann H-Erich , Christiani David C. , Rennert Gad , Arnold Susanne M. , Goodman Gary E. , Field John K. , Davies Michael P.A. , Shete Sanjay , Marchand Loïc Le , Liu Geoffrey , Hung Rayjean J. , Andrew Angeline S. , Kiemeney Lambertus A. , Sun Ryan , Zienolddiny Shanbeh , Grankvist Kjell , Johansson Mikael , Caporaso Neil E. , Cox Angela , Hong Yun-Chul , Lazarus Philip , Schabath Matthew B. , Aldrich Melinda C. , Schwartz Ann G. , Gorlov Ivan , Purrington Kristen S. , Yang Ping , Liu Yanhong , Bailey-Wilson Joan E. , Pinney Susan M. , Mandal Diptasri , Willey James C. , Gaba Colette , Brennan Paul , Xia Jun , Shen Hongbing , Amos Christopher I.
Published: March 2024

Supplementary Table S1 displays the number of ever- and never-smokers from each of the ten studies.
Figure S2 from Lung Cancer in Ever- and Never-Smokers: Findings from Multi-Population GWAS Studies
Authors: Li Yafang , Xiao Xiangjun , Li Jianrong , Han Younghun , Cheng Chao , Fernandes Gail F. , Slewitzke Shannon E. , Rosenberg Susan M. , Zhu Meng , Byun Jinyoung , Bossé Yohan , McKay James D. , Albanes Demetrios , Lam Stephen , Tardon Adonina , Chen Chu , Bojesen Stig E. , Landi Maria T. , Johansson Mattias , Risch Angela , Bickeböller Heike , Wichmann H-Erich , Christiani David C. , Rennert Gad , Arnold Susanne M. , Goodman Gary E. , Field John K. , Davies Michael P.A. , Shete Sanjay , Marchand Loïc Le , Liu Geoffrey , Hung Rayjean J. , Andrew Angeline S. , Kiemeney Lambertus A. , Sun Ryan , Zienolddiny Shanbeh , Grankvist Kjell , Johansson Mikael , Caporaso Neil E. , Cox Angela , Hong Yun-Chul , Lazarus Philip , Schabath Matthew B. , Aldrich Melinda C. , Schwartz Ann G. , Gorlov Ivan , Purrington Kristen S. , Yang Ping , Liu Yanhong , Bailey-Wilson Joan E. , Pinney Susan M. , Mandal Diptasri , Willey James C. , Gaba Colette , Brennan Paul , Xia Jun , Shen Hongbing , Amos Christopher I.
Published: March 2024

Supplementary Figure S2 shows the bar chart of lung cancer risk across different smoking strata in EUR, EAS and AFR.
Table S1 from Mitochondrial DNA Haplogroups and SNPs: Risk Factors in Multiple Cancers Based on a Cross-Tumor Analysis in Chinese Population
Authors: Chen Dongbo , Yan Zeyu , Yuan Qing , Xie Fanfan , Liu Yang , Feng Zehui , Wang Zhenni , Zhou Feng , Xing Jinliang , Zhang Zhaohui , Wang Fuli , Guo Xu
Published: March 2024

The frequency of mtDNA haplogroups in healthy controls from public data and in-house data.
Table S3 from Hematocrit Is Associated with Cancer-Related Fatigue in Colorectal Cancer Survivors: A Longitudinal Analysis
Authors: Kiebach Joann , de Vries-ten Have Judith , van Duijnhoven Fränzel J.B. , Kok Dieuwertje E. , van Lanen Anne-Sophie , Kouwenhoven Ewout A. , de Wilt Johannes H.W. , Schrauwen Ruud W.M. , Kampman Ellen , Winkels Renate M. , Wesselink Evertine
Published: March 2024

Sensitivity analyses on the association between hematocrit levels and severity of CRF at the different timepoints among survivors that were fatigued or anemic at least once during the study period
Data from Maternal Prenatal Use of Alcohol, Tobacco, and Illicit Drugs and Associations with Childhood Cancer Subtypes
Authors: Wimberly Courtney E. , Gulrajani Natalie B. , Russ Jeffrey B. , Landi Daniel , Wiemels Joseph L. , Towry Lisa , Wiencke John K. , Walsh Kyle M.
Published: March 2024

AbstractBackground:
The association between childhood cancer risk and maternal prenatal substance use/abuse remains uncertain due to modest sample sizes and heterogeneous study designs.
Methods:
We surveyed parents of children with cancer regarding maternal gestational use of tobacco, alcohol, and illicit drugs, using a Likert-type scale, and demographic, perinatal, and clinical variables. Multivariable log-Poisson regression assessed differences in frequency of prenatal substance use across fifteen childhood cancer subtypes, adjusting for birthweight, gestational age, and demographic factors.
Results:
Respondents from 3,145 unique families completed the survey (92% biological mothers). A minority reported gestational use of tobacco products (14%), illicit drugs including marijuana or cocaine (4%), or more than a moderate amount of alcohol (2%). Prenatal illicit drug use was associated with increased prevalence of intracranial embryonal tumors [prevalence ratio (PR) = 1.94; confidence interval [CI], 1.05–3.58], including medulloblastoma (PR = 1.82) and supratentorial primitive neuroectodermal tumors (PNET; PR = 2.66), and was also associated with retinoblastoma (PR = 3.11; CI, 1.20–8.08). Moderate to heavy alcohol consumption was strongly associated with elevated prevalence of non-Hodgkin lymphoma (PR = 5.94; CI, 1.84–19.21). Prenatal smoking was not associated with elevated prevalence of any childhood cancer subtype.
Conclusions:
We identify novel associations between illicit drug use during pregnancy and increased prevalence of nonglioma central nervous system tumors, including medulloblastoma, supratentorial PNETs, and retinoblastoma. Gestational exposure to alcohol was positively associated with non-Hodgkin lymphoma.
Impact:
Although alcohol and tobacco use during pregnancy has declined, gestational cannabis use has risen. Investigating its impact on neurodevelopment and brain tumorigenesis is vital, with important implications for childhood cancer research and public health education.
Data from Isolating the Drivers of Racial Inequities in Prostate Cancer Treatment
Authors: Hammarlund Noah , Holt Sarah K. , Basu Anirban , Etzioni Ruth , Morehead Danté , Lee Jenney R. , Wolff Erika M. , Gore John L. , Nyame Yaw A.
Published: March 2024

AbstractBackground:
Black individuals in the United States are less likely than White individuals to receive curative therapies despite a 2-fold higher risk of prostate cancer death. While research has described treatment inequities, few studies have investigated underlying causes.
Methods:
We analyzed a cohort of 40,137 Medicare beneficiaries (66 and older) linked to the Surveillance Epidemiology and End Results (SEER) cancer registry who had clinically significant, non-metastatic (cT1-4N0M0, grade group 2–5) prostate cancer (diagnosed 2010–2015). Using the Kitagawa-Oaxaca-Blinder decomposition, we assessed the contributions of patient health and health care delivery on the racial difference in localized prostate cancer treatments (radical prostatectomy or radiation). Patient health consisted of comorbid diagnoses, tumor characteristics, SEER site, diagnosis year, and age. Health care delivery was captured as a prediction model with these health variables as predictors of treatment, reflecting current treatment patterns.
Results:
A total of 72.1% and 78.6% of Black and White patients received definitive treatment, respectively, a difference of 6.5 percentage points. An estimated 15% [95% confidence interval (CI): 6–24] of this treatment difference was explained by measured differences in patient health, leaving the remaining estimated 85% (95% CI: 74–94) attributable to a potentially broad range of health care delivery factors. Limitations included insufficient data to explore how specific health care delivery factors, including structural racism and social determinants, impact differential treatment.
Conclusions:
Our results show the inadequacy of patient health differences as an explanation of the treatment inequity.
Impact:
Investing in studies and interventions that support equitable health care delivery for Black individuals with prostate cancer will contribute to improved outcomes.
Supplementary Table S3 from GATA-3–dependent Gene Transcription is Impaired upon HDAC Inhibition
Authors: Geng Xiangrong , Wang Chenguang , Abdelrahman Suhaib , Perera Thilini , Saed Badeia , Hu Ying S. , Wolfe Ashley , Reneau John , Murga-Zamalloa Carlos , Wilcox Ryan A.
Published: March 2024

List of HDACi altered GATA-3 target genes
Supplementary Figure S1 from GATA-3–dependent Gene Transcription is Impaired upon HDAC Inhibition
Authors: Geng Xiangrong , Wang Chenguang , Abdelrahman Suhaib , Perera Thilini , Saed Badeia , Hu Ying S. , Wolfe Ashley , Reneau John , Murga-Zamalloa Carlos , Wilcox Ryan A.
Published: March 2024

BHLHE40 and KLF6 are transcriptionally activated by GATA-3, and their expression impaired upon HDAC inhibition
Supplementary Table S2 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Authors: Mooney Brian , Negri Gian Luca , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Spencer Miko Sandra E. , Weiner Amber K. , Radaoui Alexander B. , Shraim Rawan , Lizardo Michael M. , Hughes Christopher S. , Li Amy , El-Naggar Amal M. , Rouleau Melanie , Li Wei , Dimitrov Dimiter S. , Kurmasheva Raushan T. , Houghton Peter J. , Diskin Sharon J. , Maris John M. , Morin Gregg B. , Sorensen Poul H.
Published: March 2024

Surface protein annotation based on COMPARTMENTS and GO
Supplementary Table S1 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Authors: Mooney Brian , Negri Gian Luca , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Spencer Miko Sandra E. , Weiner Amber K. , Radaoui Alexander B. , Shraim Rawan , Lizardo Michael M. , Hughes Christopher S. , Li Amy , El-Naggar Amal M. , Rouleau Melanie , Li Wei , Dimitrov Dimiter S. , Kurmasheva Raushan T. , Houghton Peter J. , Diskin Sharon J. , Maris John M. , Morin Gregg B. , Sorensen Poul H.
Published: March 2024

SuperMix cell lines
Supplementary Figure S6 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Authors: Mooney Brian , Negri Gian Luca , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Spencer Miko Sandra E. , Weiner Amber K. , Radaoui Alexander B. , Shraim Rawan , Lizardo Michael M. , Hughes Christopher S. , Li Amy , El-Naggar Amal M. , Rouleau Melanie , Li Wei , Dimitrov Dimiter S. , Kurmasheva Raushan T. , Houghton Peter J. , Diskin Sharon J. , Maris John M. , Morin Gregg B. , Sorensen Poul H.
Published: March 2024

Expression of ATP11C, SLCO5A1, and STEAP2 in publicly available datasets.
Supplementary Figure S3 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Authors: Mooney Brian , Negri Gian Luca , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Spencer Miko Sandra E. , Weiner Amber K. , Radaoui Alexander B. , Shraim Rawan , Lizardo Michael M. , Hughes Christopher S. , Li Amy , El-Naggar Amal M. , Rouleau Melanie , Li Wei , Dimitrov Dimiter S. , Kurmasheva Raushan T. , Houghton Peter J. , Diskin Sharon J. , Maris John M. , Morin Gregg B. , Sorensen Poul H.
Published: March 2024

Consensus clustering of proteomics data.
Supplementary Figure S14 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Authors: Mooney Brian , Negri Gian Luca , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Spencer Miko Sandra E. , Weiner Amber K. , Radaoui Alexander B. , Shraim Rawan , Lizardo Michael M. , Hughes Christopher S. , Li Amy , El-Naggar Amal M. , Rouleau Melanie , Li Wei , Dimitrov Dimiter S. , Kurmasheva Raushan T. , Houghton Peter J. , Diskin Sharon J. , Maris John M. , Morin Gregg B. , Sorensen Poul H.
Published: March 2024

ENPP1 is expressed at higher levels in non-metastatic EwS vs metastatic EwS.
Supplementary Figure S13 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Authors: Mooney Brian , Negri Gian Luca , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Spencer Miko Sandra E. , Weiner Amber K. , Radaoui Alexander B. , Shraim Rawan , Lizardo Michael M. , Hughes Christopher S. , Li Amy , El-Naggar Amal M. , Rouleau Melanie , Li Wei , Dimitrov Dimiter S. , Kurmasheva Raushan T. , Houghton Peter J. , Diskin Sharon J. , Maris John M. , Morin Gregg B. , Sorensen Poul H.
Published: March 2024

ENPP1 immunofluorescence.
Supplementary Figure S12 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Authors: Mooney Brian , Negri Gian Luca , Shyp Taras , Delaidelli Alberto , Zhang Hai-Feng , Spencer Miko Sandra E. , Weiner Amber K. , Radaoui Alexander B. , Shraim Rawan , Lizardo Michael M. , Hughes Christopher S. , Li Amy , El-Naggar Amal M. , Rouleau Melanie , Li Wei , Dimitrov Dimiter S. , Kurmasheva Raushan T. , Houghton Peter J. , Diskin Sharon J. , Maris John M. , Morin Gregg B. , Sorensen Poul H.
Published: March 2024

CDH11 is a surface protein in EwS
Supplementary Table S3 from Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression
Authors: Mitchell Dana K. , Burgess Breanne , White Emily E. , Smith Abbi E. , Sierra Potchanant Elizabeth A. , Mang Henry , Hickey Brooke E. , Lu Qingbo , Qian Shaomin , Bessler Waylan , Li Xiaohong , Jiang Li , Brewster Kylee , Temm Constance , Horvai Andrew , Albright Eric A. , Fishel Melissa L. , Pratilas Christine A. , Angus Steven P. , Clapp D. Wade , Rhodes Steven D.
Published: March 2024

Normalization constants (mRNA_normalization_factors) and mean squared error for each sample computed based on selected housekeeping genes (HK_MSE).
Supplementary Table S2 from Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression
Authors: Mitchell Dana K. , Burgess Breanne , White Emily E. , Smith Abbi E. , Sierra Potchanant Elizabeth A. , Mang Henry , Hickey Brooke E. , Lu Qingbo , Qian Shaomin , Bessler Waylan , Li Xiaohong , Jiang Li , Brewster Kylee , Temm Constance , Horvai Andrew , Albright Eric A. , Fishel Melissa L. , Pratilas Christine A. , Angus Steven P. , Clapp D. Wade , Rhodes Steven D.
Published: March 2024

Probes excluded due to low signal (below background).
Supplementary Table S1 from Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression
Authors: Mitchell Dana K. , Burgess Breanne , White Emily E. , Smith Abbi E. , Sierra Potchanant Elizabeth A. , Mang Henry , Hickey Brooke E. , Lu Qingbo , Qian Shaomin , Bessler Waylan , Li Xiaohong , Jiang Li , Brewster Kylee , Temm Constance , Horvai Andrew , Albright Eric A. , Fishel Melissa L. , Pratilas Christine A. , Angus Steven P. , Clapp D. Wade , Rhodes Steven D.
Published: March 2024

Raw count matrix and probe annotations.
Supplementary Figure S6 from Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression
Authors: Mitchell Dana K. , Burgess Breanne , White Emily E. , Smith Abbi E. , Sierra Potchanant Elizabeth A. , Mang Henry , Hickey Brooke E. , Lu Qingbo , Qian Shaomin , Bessler Waylan , Li Xiaohong , Jiang Li , Brewster Kylee , Temm Constance , Horvai Andrew , Albright Eric A. , Fishel Melissa L. , Pratilas Christine A. , Angus Steven P. , Clapp D. Wade , Rhodes Steven D.
Published: March 2024

Supplemental Figure 6. Upregulation of cell proliferation and survival/apoptosis gene signatures in MPNST and Cluster 3 tumors.
Supplementary Figure S10 from Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression
Authors: Mitchell Dana K. , Burgess Breanne , White Emily E. , Smith Abbi E. , Sierra Potchanant Elizabeth A. , Mang Henry , Hickey Brooke E. , Lu Qingbo , Qian Shaomin , Bessler Waylan , Li Xiaohong , Jiang Li , Brewster Kylee , Temm Constance , Horvai Andrew , Albright Eric A. , Fishel Melissa L. , Pratilas Christine A. , Angus Steven P. , Clapp D. Wade , Rhodes Steven D.
Published: March 2024

Supplemental Figure 10. Survivin inhibition with LQZ-7I abrogates viability of human MPNST and murine primary Schwann cell precursors.
Table S9 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S9: [89Zr]Zr-DFO-YS5 %IA/g in the RPMI8226 subcutaneous xenograft models.
Table S8 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S8: %IA/Organ of [89Zr]Zr-DFO-YS5 in subcutaneous MM.1S CD46 (-/-) tumor model.
Table S4 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S4: %IA/Organ of [89Zr]Zr-DFO-YS5 + blocking studies with 50 fold excess of cold YS5 in subcutaneous MM.1S tumor model.
Table S32 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S32: [18F]-FDG % IA/Organ in the RPMI8226 systemic tumor model.
Table S31 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S31: [18F]-FDG %IA/g in the RPMI8226 systemic tumor model.
Table S27 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S27: [18F]-FDG %IA/g biodistribution in the MM.1S systemic tumor model.
Table S26 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S26: [89Zr]Zr-DFO-YS5+ 50 fold YS5 %IA/Organ in the MM.1S systemic tumor model.
Table S22 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S22: [18F]-FDG %IA/Organ in the ANBL6 subcutaneous xenograft models.
Table S20 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S20: [18F]-FDG %IA/Organ in the RPMI8226 subcutaneous xenograft models.
Table S17 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S17: [18F]-FDG %IA/g in the MM.1S subcutaneous xenograft model.
Table S10 from CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Authors: Wadhwa Anju , Wang Sinan , Patiño-Escobar Bonell , Bidkar Anil P. , Bobba Kondapa Naidu , Chan Emily , Meher Niranjan , Bidlingmaier Scott , Su Yang , Dhrona Suchi , Geng Huimin , Sarin Vishesh , VanBrocklin Henry F. , Wilson David M. , He Jiang , Zhang Li , Steri Veronica , Wong Sandy W. , Martin Thomas G. , Seo Youngho , Liu Bin , Wiita Arun P. , Flavell Robert R.
Published: March 2024

Table S10: [89Zr]Zr-DFO-YS5 % IA/Organ in the RPMI8226 subcutaneous xenograft models.
Supplementary Table S4 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer
Authors: Oaknin Ana , Ghamande Sharad A. , Kasamatsu Yuka , Gil-Martin Marta , Grau-Bejar Juan Francisco , Garcia-Duran Carmen , Sato Masashi , Siddiqui Abdul , Chaudhary Surendra Pal , Vugmeyster Yulia , Hasegawa Kosei
Published: March 2024

Table S4. Pharmacokinetic exposure summary. AUC, area under the curve; Ceoi, concentration at end of infusion; Ctrough, concentration at the end of the dosing interval; CV, coefficient of variation; NA, not applicable; popPK, population pharmacokinetic; SD, standard deviation.
Supplementary Table S1 from Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer
Authors: Oaknin Ana , Ghamande Sharad A. , Kasamatsu Yuka , Gil-Martin Marta , Grau-Bejar Juan Francisco , Garcia-Duran Carmen , Sato Masashi , Siddiqui Abdul , Chaudhary Surendra Pal , Vugmeyster Yulia , Hasegawa Kosei
Published: March 2024

Table S1. Median duration of therapy. IQR, interquartile range; NA, not applicable.
Table 1 from The Effect of Diet on Breast Cancer Recurrence: The DIANA-5 Randomized Trial
Authors: Berrino Franco , Villarini Anna , Gargano Giuliana , Krogh Vittorio , Grioni Sara , Bellegotti Manuela , Venturelli Elisabetta , Raimondi Milena , Traina Adele , Zarcone Maurizio , Amodio Rosalba , Mano Maria Piera , Johansson Harriet , Panico Salvatore , Santucci de Magistris Maria , Barbero Maggiorino , Gavazza Cristina , Mercandino Angelica , Consolaro Elena , Galasso Rocco , Del Riccio Luciana , Bassi Maria Chiara , Simeoni Milena , Premoli Paolo , Pasanisi Patrizia , Bonanni Bernardo , Bruno Eleonora
Published: March 2024

Representativeness of Study Participants
Supplementary Data 1 from The Effect of Diet on Breast Cancer Recurrence: The DIANA-5 Randomized Trial
Authors: Berrino Franco , Villarini Anna , Gargano Giuliana , Krogh Vittorio , Grioni Sara , Bellegotti Manuela , Venturelli Elisabetta , Raimondi Milena , Traina Adele , Zarcone Maurizio , Amodio Rosalba , Mano Maria Piera , Johansson Harriet , Panico Salvatore , Santucci de Magistris Maria , Barbero Maggiorino , Gavazza Cristina , Mercandino Angelica , Consolaro Elena , Galasso Rocco , Del Riccio Luciana , Bassi Maria Chiara , Simeoni Milena , Premoli Paolo , Pasanisi Patrizia , Bonanni Bernardo , Bruno Eleonora
Published: March 2024

Supplementary Figure 1; Supplementary Figure 2; Supplementary Table 1 ; Supplementary Figure 3; Supplementary Table 2
Supplementary Table 1 from Niraparib plus Dostarlimab in Pleural Mesothelioma or Non–Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial
Authors: Passiglia Francesco , Righi Luisella , Bironzo Paolo , Listì Angela , Farinea Giovanni , Capelletto Enrica , Novello Silvia , Merlini Alessandra , Scagliotti Giorgio V.
Published: March 2024

Supplementary Table 1. Representativeness of Study Participants.
Supplementary Figure Legends from FGFR1 Signaling Facilitates Obesity-Driven Pulmonary Outgrowth in Metastatic Breast Cancer
Authors: Kulkoyluoglu Cotul Eylem , Safdar Muhammad Hassan , Paez Sebastian Juan , Kulkarni Aneesha , Ayers Mitchell G. , Lin Hang , Xianyu Zilin , Teegarden Dorothy , Hursting Stephen D. , Wendt Michael K.
Published: March 2024

These are the figure legends for Supplementary figures 1 and 2.
Figure S2 from FGFR1 Signaling Facilitates Obesity-Driven Pulmonary Outgrowth in Metastatic Breast Cancer
Authors: Kulkoyluoglu Cotul Eylem , Safdar Muhammad Hassan , Paez Sebastian Juan , Kulkarni Aneesha , Ayers Mitchell G. , Lin Hang , Xianyu Zilin , Teegarden Dorothy , Hursting Stephen D. , Wendt Michael K.
Published: March 2024

Paracrine FGF2 can induce the outgrowth of D2.OR cells in 3D culture.
Figure S1 from FGFR1 Signaling Facilitates Obesity-Driven Pulmonary Outgrowth in Metastatic Breast Cancer
Authors: Kulkoyluoglu Cotul Eylem , Safdar Muhammad Hassan , Paez Sebastian Juan , Kulkarni Aneesha , Ayers Mitchell G. , Lin Hang , Xianyu Zilin , Teegarden Dorothy , Hursting Stephen D. , Wendt Michael K.
Published: March 2024

Pemigatinib blocks FGF2-induced signaling and 3D outgrowth of D2.OR cells via inhibition of FGFR1.
Supplementary Table 1 from Single-Cell Transcriptomics Reveals Pre-existing COVID-19 Vulnerability Factors in Lung Cancer Patients
Authors: Liu Wendao , Li Wenbo , Zhao Zhongming
Published: March 2024

Supplementary Table 1. The clinical characteristics of included human subjects.
Supplementary Video 1B from Mitochondria Transfer by Platelet-Derived Microparticles Regulates Breast Cancer Bioenergetic States and Malignant Features
Authors: Veilleux Vanessa , Pichaud Nicolas , Boudreau Luc H. , Robichaud Gilles A.
Published: March 2024

Supplementary Video 1B displays the intracellular localization of internalized fluorescent microparticles in MCF7 cells using 3D confocal zStacks imaging.
Supplementary Figure 4 from Single-Cell Transcriptomics Reveals Pre-existing COVID-19 Vulnerability Factors in Lung Cancer Patients
Authors: Liu Wendao , Li Wenbo , Zhao Zhongming
Published: March 2024

Supplementary Figure 4. T cell subpopulations and LGALS9 signaling.
Supplementary Figure 1 from Single-Cell Transcriptomics Reveals Pre-existing COVID-19 Vulnerability Factors in Lung Cancer Patients
Authors: Liu Wendao , Li Wenbo , Zhao Zhongming
Published: March 2024

Supplementary Figure 1. An overview of four-level hierarchical annotation of single cells in lung tissue.
Supplementary Figure 4 from Mitochondria Transfer by Platelet-Derived Microparticles Regulates Breast Cancer Bioenergetic States and Malignant Features
Authors: Veilleux Vanessa , Pichaud Nicolas , Boudreau Luc H. , Robichaud Gilles A.
Published: March 2024

Figure S4 demonstrates that microparticles contain mitochondria cargo using PCR to detect mitochondrial DNA.
Table S2 from TNFRSF19 within the 13q12.12 Risk Locus Functions as a Lung Cancer Suppressor by Binding Wnt3a to Inhibit Wnt/β-Catenin Signaling
Authors: Zuo Xianglin , Wang Xuchun , Ma Tingzheng , Chen Shuhan , Cao Pingping , Cheng He , Yang Nan , Han Xiao , Gao Wei , Liu Xiaoyu , Sun Yujie
Published: March 2024

Antibodies used in the present study
Supplementary Table 6 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
Authors: Savardekar Himanshu , Allen Carter , Jeon Hyeongseon , Li Jianying , Quiroga Dionisia , Schwarz Emily , Wu Richard C. , Zelinskas Sara , Lapurga Gabriella , Abreo Alexander , Stiff Andrew , Shaffer Jami , Blaser Bradley W. , Old Matthew , Wesolowski Robert , Xin Gang , Kendra Kari L. , Chung Dongjun , Carson William E.
Published: March 2024

Baseline MDSC Gene Expression.
Supplemental Table S1 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Authors: Barravecchia Ivana , Lee Jennifer M. , Manassa Jason , Magnuson Brian , Ferris Sarah F. , Cavanaugh Sophia , Steele Nina G. , Espinoza Carlos E. , Galban Craig J. , Ramnath Nithya , Frankel Timothy L. , Pasca di Magliano Marina , Galban Stefanie
Published: March 2024

Supplemental Table S1. Stains and antibodies used for mIHC.
Supplemental Figure S3 from Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Authors: Barravecchia Ivana , Lee Jennifer M. , Manassa Jason , Magnuson Brian , Ferris Sarah F. , Cavanaugh Sophia , Steele Nina G. , Espinoza Carlos E. , Galban Craig J. , Ramnath Nithya , Frankel Timothy L. , Pasca di Magliano Marina , Galban Stefanie
Published: March 2024

Supplemental Figure S3. PCA biplot (PC1 and PC2) of VST-normalized gene counts for the top 500 most variable genes.
Supplementary Table 1 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
Authors: Savardekar Himanshu , Allen Carter , Jeon Hyeongseon , Li Jianying , Quiroga Dionisia , Schwarz Emily , Wu Richard C. , Zelinskas Sara , Lapurga Gabriella , Abreo Alexander , Stiff Andrew , Shaffer Jami , Blaser Bradley W. , Old Matthew , Wesolowski Robert , Xin Gang , Kendra Kari L. , Chung Dongjun , Carson William E.
Published: March 2024

Reagent Information.
Supplementary Figure 8 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
Authors: Savardekar Himanshu , Allen Carter , Jeon Hyeongseon , Li Jianying , Quiroga Dionisia , Schwarz Emily , Wu Richard C. , Zelinskas Sara , Lapurga Gabriella , Abreo Alexander , Stiff Andrew , Shaffer Jami , Blaser Bradley W. , Old Matthew , Wesolowski Robert , Xin Gang , Kendra Kari L. , Chung Dongjun , Carson William E.
Published: March 2024

FACS purified MDSC viability after 24h DMSO or ibrutinib treatment.
Supplementary Table 5 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Authors: Shao Xiaowen , Dang Yamei , Zhang Tingting , Bai Nan , Huang Jianing , Guo Mengya , Sun Li , Li Minghe , Sun Xiao , Zhang Xinran , Han Feng , Zhang Ning , Zhuang Hao , Li Yongmei
Published: March 2024

Summary of the sequencing coverage and quality statistics of the RIP-Seq analysis.
Supplementary Figure 5 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
Authors: Savardekar Himanshu , Allen Carter , Jeon Hyeongseon , Li Jianying , Quiroga Dionisia , Schwarz Emily , Wu Richard C. , Zelinskas Sara , Lapurga Gabriella , Abreo Alexander , Stiff Andrew , Shaffer Jami , Blaser Bradley W. , Old Matthew , Wesolowski Robert , Xin Gang , Kendra Kari L. , Chung Dongjun , Carson William E.
Published: March 2024

Pathway analysis results from IPA of melanoma MDSC treated with DMSO control or 4h ibrutinib.
Supplementary Figure 3 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
Authors: Savardekar Himanshu , Allen Carter , Jeon Hyeongseon , Li Jianying , Quiroga Dionisia , Schwarz Emily , Wu Richard C. , Zelinskas Sara , Lapurga Gabriella , Abreo Alexander , Stiff Andrew , Shaffer Jami , Blaser Bradley W. , Old Matthew , Wesolowski Robert , Xin Gang , Kendra Kari L. , Chung Dongjun , Carson William E.
Published: March 2024

Comparison of melanoma MDSC to breast MDSC (A-B) and to head and neck MDSC (C-D).
Supplementary Figure 1 from Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase
Authors: Savardekar Himanshu , Allen Carter , Jeon Hyeongseon , Li Jianying , Quiroga Dionisia , Schwarz Emily , Wu Richard C. , Zelinskas Sara , Lapurga Gabriella , Abreo Alexander , Stiff Andrew , Shaffer Jami , Blaser Bradley W. , Old Matthew , Wesolowski Robert , Xin Gang , Kendra Kari L. , Chung Dongjun , Carson William E.
Published: March 2024

MDSC isolation via FACS.
Supplementary Figure 9 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Authors: Shao Xiaowen , Dang Yamei , Zhang Tingting , Bai Nan , Huang Jianing , Guo Mengya , Sun Li , Li Minghe , Sun Xiao , Zhang Xinran , Han Feng , Zhang Ning , Zhuang Hao , Li Yongmei
Published: March 2024

LINC00869 promotes HCC cells migration and invasion via activating Cdc42-WASp pathway.
Supplementary Figure 2 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Authors: Shao Xiaowen , Dang Yamei , Zhang Tingting , Bai Nan , Huang Jianing , Guo Mengya , Sun Li , Li Minghe , Sun Xiao , Zhang Xinran , Han Feng , Zhang Ning , Zhuang Hao , Li Yongmei
Published: March 2024

LINC00869 interacts with actin-related proteins WASp and Arp2.
Supplementary Figure 1 from LINC00869 Promotes Hepatocellular Carcinoma Metastasis via Protrusion Formation
Authors: Shao Xiaowen , Dang Yamei , Zhang Tingting , Bai Nan , Huang Jianing , Guo Mengya , Sun Li , Li Minghe , Sun Xiao , Zhang Xinran , Han Feng , Zhang Ning , Zhuang Hao , Li Yongmei
Published: March 2024

Heatmap of enriched lncRNAs binding to WASp and Arp2 protein determined by RIP-seq.
Data from Mitochondria Transfer by Platelet-Derived Microparticles Regulates Breast Cancer Bioenergetic States and Malignant Features
Authors: Veilleux Vanessa , Pichaud Nicolas , Boudreau Luc H. , Robichaud Gilles A.
Published: March 2024

Abstract
An increasing number of studies show that platelets as well as platelet-derived microparticles (PMP) play significant roles in cancer malignancy and disease progression. Particularly, PMPs have the capacity to interact and internalize within target cells resulting in the transfer of their bioactive cargo, which can modulate the signaling and activation processes of recipient cells. We recently identified a new subpopulation of these vesicles (termed mitoMPs), which contain functional mitochondria. Given the predominant role of mitochondria in cancer cell metabolism and disease progression, we set out to investigate the impact of mitoMPs on breast cancer metabolic reprograming and phenotypic processes leading to malignancy. Interestingly, we observed that recipient cell permeability to PMP internalization varied among the breast cancer cell types evaluated in our study. Specifically, cells permissive to mitoMPs acquire mitochondrial-dependent functions, which stimulate increased cellular oxygen consumption rates and intracellular ATP levels. In addition, cancer cells co-incubated with PMPs display enhanced malignant features in terms of migration and invasion. Most importantly, the cancer aggressive processes and notable metabolic plasticity induced by PMPs were highly dependent on the functional status of the mitoMP-packaged mitochondria. These findings characterize a new mechanism by which breast cancer cells acquire foreign mitochondria resulting in the gain of metabolic processes and malignant features. A better understanding of these mechanisms may provide therapeutic opportunities through PMP blockade to deprive cancer cells from resources vital in disease progression.
Implications:
We show that the transfer of foreign mitochondria by microparticles modulates recipient cancer cell metabolic plasticity, leading to greater malignant processes.
Abstract A018: A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
Authors: Dockery Lauren E. , Priebe Anna , Duska Linda , Green Angela K. , Mathews Cara , Musa Fernanda , O'Malley David , Puechl Allison , Ding Li , Schmid Anita N. , Navarro Willis H. , Slomovitz Brian , Moore Kathleen
Published: March 2024

Introduction/Objective: This trial in progress is designed to evaluate the anti-tumor activity of nab-sirolimus in combination with letrozole in patients with advanced or recurrent endometrioid endometrial carcinoma (EEC). Despite recent pivotal data demonstrating improved outcomes with immunotherapy plus chemotherapy, regardless of mismatch repair status, alternative treatment options, particularly for advanced or recurrent EEC remain necessary. Dysregulation of mammalian target of rapamycin (mTOR) signaling is implicated in the pathology of EEC, in which >80% harbor PTEN or PI3K/AKT/mTOR pathway alterations. Moreover, crosstalk between mTOR and estrogen receptor signaling pathways is associated with endocrine resistance. GOG-3007 and other phase 2 studies have demonstrated that the combination of conventional mTOR inhibitors (mTORis) and endocrine therapy provides clinical benefit in patients with EC. nab-Sirolimus, a nanoparticle injectable form of mTORi, is approved in the USA for malignant perivascular epithelioid cell tumor. Preclinical data of nab-sirolimus demonstrated improved tumor accumulation, mTOR inhibition, and tumor growth suppression compared with conventional mTORis. We hypothesize that nab-sirolimus in combination with letrozole may produce synergistic antitumor activity in patients with recurrent EEC. Methods: In this phase 2, open-label, single-arm, multicenter study (NCT05997017), nab-sirolimus (100 mg/m2, intravenous, on days 1 and 8 of each 21-day cycle) and letrozole (2.5 mg, oral, daily) are administered to patients (~29 planned) with clinically confirmed, advanced, or recurrent EEC. Eligibility criteria include age ≥18 years, ≤1 prior chemo-based regimen, Eastern Cooperative Oncology Group performance status score 0 or 1, naïve to mTORi, and measurable disease (per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1). The primary endpoint is best overall response rate by RECIST v1.1. Key secondary endpoints include duration of response, progression-free survival, overall survival, and safety. The relationship between biomarkers and response outcomes is an exploratory endpoint.

Citation Format: Lauren E. Dockery, Anna Priebe, Linda Duska, Angela K. Green, Cara Mathews, Fernanda Musa, David O'Malley, Allison Puechl, Li Ding, Anita N. Schmid, Willis H. Navarro, Brian Slomovitz, Kathleen Moore. A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl):Abstract nr A018.
Abstract B014: Patient-derived organoid models for drug screening in molecular subtypes of endometrial cancer
Authors: Liu Dongli , Powell Elyse , Wan King Man , Athavale Ramanand , Loo Christine , Ford Caroline E.
Published: March 2024

Introduction: The lack of reliable pre-clinical models has significantly impeded the progress of drug discovery for specific molecular subtypes of endometrial cancer. This study aimed to develop patient-derived organoid models for use in preclinical screening of novel and repurposed therapies in endometrial cancer molecular subtypes. Method: Endometrial cancer tissue (n=27) and ascites fluid (n=1) were collected for this study (ethics approval SESLHD HREC 2021_ETH11975 and 19/001) from patients of various subtypes (17 endometrioid, 3 high grade serous, 2 carcinosarcoma, 2 clear cell, 3 mixed) undergoing treatment at the Royal Hospital for Women and Prince of Wales Private Hospital in Sydney, Australia. Tumor cells were isolated, embedded in 70% Matrigel and cultured in defined culture medium to form organoids. Molecular subtyping of organoids and matched parental tissue was undertaken by mismatch repair (MMR) and p53 immunohistochemistry (IHC), and sequencing of POLE exonuclease domain mutations (EDMs). A unique matched two-dimensional (2D) cell line and three-dimensional (3D) organoid culture derived from ascites isolated from a high grade serous endometrial cancer patient was established. These molecularly stratified pre-clinical models were then used to test drug activity. As a proof of principle, response to paclitaxel and carboplatin was undertaken. Result: 20 organoids representing all major molecular subtypes were established (71% success rate), including one derived from ascites fluid. Organoids are presented with either a cystic or solid structure that highly resembles the morphology of the original tissue. Organoid culture can faithfully retain key features including MMR, p53 status as well as POLE EDMs of the parental tissue. The drug screening results identified contrasting responses of 2D and 3D models obtained from the same patient tissue, highlighting the importance of selecting appropriate pre-clinical models for drug development and testing. Conclusion: This study demonstrated that patient-derived organoids can successfully recapitulate the molecular characterization of endometrial cancer. Molecularly defined organoids represent a promising preclinical resource for drug screening in endometrial cancer. In addition, the model structure should be taken into account while conducting drug screening.

Citation Format: Dongli Liu, Elyse Powell, King Man Wan, Ramanand Athavale, Christine Loo, Caroline E. Ford. Patient-derived organoid models for drug screening in molecular subtypes of endometrial cancer [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl):Abstract nr B014.
Abstract B018: MYC is sufficient to generate mid-life high-grade serous ovarian and serous endometrial carcinomas in a BRCA wild type p53-R270H mouse model
Authors: Blackman Alexandra , Rees Amy , Bowers Rob , Jones Christian , Vaena Silvia , Carter Shelby , Villamor Evan , Evans Della , Fullbright George , Long David , Spruill Laura , Romeo Martin , Helke Kristi , Emanuel Anthony , Delaney Joe
Published: March 2024

Genetically engineered mouse models (GEMM) have fundamentally changed how cancer etiology, early detection, and treatment can be understood. Mouse models have been developed that support the fallopian tube as the origin of some ovarian cancers. However, serous endometrial cancer is a much rarer gynecologic cancer with fewer models available. The genetics of serous endometrial cancer are very similar that of high-grade serous ovarian cancer. The most common mutation found in both high-grade serous ovarian cancer and serous uterine cancer is p53 and in humans, MYC is amongst the most amplified genes in both tyeps of cancer. We developed a GEMM of high-grade serous ovarian cancer by using a fallopian tube epithelium specific promoter Ovgp1 to express MYC and dominant negative mutant p53-R270H. Female mice developed lethal cancer at an average of 15.1 months. Histopathological examination of mice revealed HGSOC characteristics including nuclear p53 and nuclear MYC in clusters of cells within the fallopian tube epithelium and ovarian surface epithelium. Unexpectedly, nuclear p53 and MYC clustered cell expression was also identified in the uterine luminal epithelium, possibly from intraepithelial metastasis from the fallopian tube epithelium. Extracted tumor cells exhibited strong loss of heterozygosity at the p53 locus, leaving the mutant allele. Copy number alterations in these cancer cells were prevalent, disrupting a large fraction of genes. Transcriptome profiles most closely matched human HGSOC and serous endometrial cancer. Histological and transcriptomic findings are consistent with the hypothesis that serous uterine cancer may originate from the fallopian tube epithelium.

Citation Format: Alexandra Blackman, Amy Rees, Rob Bowers, Christian Jones, Silvia Vaena, Shelby Carter, Evan Villamor, Della Evans, George Fullbright, David Long, Laura Spruill, Martin Romeo, Kristi Helke, Anthony Emanuel, Joe Delaney. MYC is sufficient to generate mid-life high-grade serous ovarian and serous endometrial carcinomas in a BRCA wild type p53-R270H mouse model [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl):Abstract nr B018.